Molecular Targeted Treatment of Metastatic Colorectal Cancer: The Cardiovascular Adverse Effects of Bevacizumab and Cetuximab

Medicine and Pharmacy Reports - Romania
doi 10.15386/cjmed-745
Full Text
Abstract

Available in full text

Categories
Medicine
Date
Authors
Publisher

Clujul Medical

Related search

Systematic Review and Economic Evaluation of Bevacizumab and Cetuximab for the Treatment of Metastatic Colorectal Cancer

Health Technology Assessment
MedicineHealth Policy
2007English

Cetuximab in First Line Treatment of Metastatic Colorectal Cancer

Farmeconomia. Health economics and therapeutic pathways
2012English

Critical Appraisal of Bevacizumab in the Treatment of Metastatic Colorectal Cancer

OncoTargets and Therapy
OncologyPharmacology
2012English

Adverse Events Associated With Bevacizumab and Chemotherapy in Older Patients With Metastatic Colorectal Cancer

Clinical Colorectal Cancer
OncologyGastroenterology
2013English

Continuation of Bevacizumab vs Cetuximab Plus Chemotherapy After First Progression in KRAS Wild-Type Metastatic Colorectal Cancer

JAMA Oncology
Cancer ResearchOncology
2019English

Metastatic Colorectal Cancer First-Line Treatment With Bevacizumab: The Impact of K-Ras Mutation

OncoTargets and Therapy
OncologyPharmacology
2013English

Current Status of Treatment of Metastatic Colorectal Cancer With Special Reference to Cetuximab and Elderly Patients

OncoTargets and Therapy
OncologyPharmacology
2008English

PCN22 Safety Profile of Bevacizumab in Metastatic Colorectal Cancer

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2011English

Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2009English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy